Trial of a Nutritional Blend to Prevent Cognitive Decline in Older Adults

Société des Produits Nestlé (SPN)362 enrolled

Overview

To demonstrate the beneficial effects of 1-year intervention with a nutritional blend of ingredients on blood levels of nutritional biomarkers known to be linked with cognitive decline in non-demented adults with subjective memory concerns aged 70+ years

This multicenter trial will be a placebo-controlled, double-blind, randomized, 2 parallel groups study. The subjects will be randomly allocated to one of two treatment groups (placebo or nutrition product). The duration of the intervention is 1 year. The total sample size at baseline is 364 subjects, consisting of non-demented adults with subjective memory concerns aged 70+ years.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE

Enrollment

362

Conditions

Cognitive Decline

Interventions

Nutrional blend of ingredients including vitamins and fish oilDIETARY_SUPPLEMENT

ControlDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 70 years 2. Spontaneous memory complaints 3. Adequate fluency in the local language to understand the inform consent form and complete any other study document 4. Sufficient vision and hearing to complete study protocol procedures based on medical judgement 5. Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication) 6. Has general health status that will not interfere with the ability to complete the study 7. Willing and able to participate and to give written consent to comply with study procedures 8. Willing to be informed in case a new clinical pathology is discovered through clinical examinations Exclusion Criteria: 1. Exhibiting a loss of independence in basic activities of daily living (ADL score \< 4) 2. MMSE score \< 24 3. Dementia as determined by DSM-V criteria 4. Suffering from diseases that are likely to be life-threatening in the short-term 5. History or presence of a severe disease (e.g., cardiovascular, hepatic, renal (e.g., End Stage Renal Disease), gastroenteral, respiratory, endocrine, neurologic, psychiatric, immunologic, or hematologic disease or other conditions) that could, in the opinion of the investigator, interfere with the subjects safety or ability to complete the trial 6. Food allergy 7. Taking omega-3 dietary supplements containing \>200 mg DHA per day during the last 6 months 8. Receiving or having received in the past 3 months a physician prescribed vitamin B12, B3 or vitamin B-complex 9. Receiving Alzheimer's Disease medication (Galantamine, Memantine Donezepil and Rivastigmine) 10. Deprived of their liberty by administrative or judicial decision, or under guardianship or admitted to a healthcare or social institution (subjects in non-assisted living facilities could be recruited). 11. Having participated in another clinical study in the previous month or is currently participating in another study. Subjects meeting one or more of the following criteria below will not be included in the PET scan and MRI-scan subset groups: 12. Wearing a pace-maker or having metal in the body which is exclusionary for MRI 13. Claustrophobic Subjects who will participate in the PET-scan and MRI-scan subset groups, will be excluded for a 1-year period of any future projects involving investigations using ionizing radiation.

Locations (1)

CHU Toulouse

Toulouse, France

Outcomes

Primary Outcomes

Changes at 1 year in levels of nutritional risk factors involved in cognitive decline with ageing relative to baseline

Plasma erythrocyte-omega 3 index